NASDAQ:INMB INmune Bio Q3 2026 Earnings Date & Estimates $1.45 -0.15 (-9.38%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$1.48 +0.04 (+2.41%) As of 10/30/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. INmune Bio is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from INmune Bio in Q3 2026INmune Bio is expected to post earnings of -$0.1467 per share on revenue of $1.88 million. In the same quarter a year earlier INmune Bio reported -$0.24 per share. INmune Bio last reported on August 6, 2026, posting -$0.05 per share and beating the -$0.2067 consensus estimate. INmune Bio has beaten the consensus EPS estimate in 6 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.1467Expected Revenue$1.88 millionPrior-Year EPS-$0.24Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.05 (Beat by +$0.1567)EPS Beat Rate6 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report INmune Bio Q3 2026 Earnings FAQ When does INmune Bio report Q3 2026 earnings? INmune Bio (NASDAQ:INMB) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is INmune Bio's Q3 2026 earnings call? INmune Bio's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for INmune Bio? Analysts expect INmune Bio to post earnings of -$0.1467 per share for Q3 2026. How much revenue is INmune Bio expected to report? The consensus revenue estimate for INmune Bio is $1.88 million for Q3 2026. INmune Bio Earnings HeadlinesINmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5thOctober 29 at 9:15 AM | globenewswire.comINmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private PlacementOctober 28, 2026 | globenewswire.comDollar Reset – Are You Prepared?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.November 1 at 1:00 AM | Porter & Company (Ad)INmune Bio (INMB) Set to Announce Quarterly Earnings on ThursdayOctober 28, 2026 | americanbankingnews.comHead-To-Head Survey: Alkermes (NASDAQ:ALKS) & INmune Bio (NASDAQ:INMB)October 24, 2026 | americanbankingnews.comINmune Bio Is A High-Potential Opportunity, But Here's Why I'm WaitingOctober 23, 2026 | seekingalpha.comSee More INmune Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like INmune Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on INmune Bio and other key companies, straight to your email. Email Address About INmune BioINmune Bio (NASDAQ:INMB) is a clinical-stage biotechnology company focused on developing treatments that harness and modulate the innate immune system. The company’s research is aimed at addressing diseases in which chronic inflammation or impaired immune function plays a significant role, including cancer, neurodegenerative disorders and certain psychiatric conditions. Its lead product candidate is XPro, a next-generation tumor necrosis factor inhibitor designed to selectively neutralize soluble TNF while preserving transmembrane TNF signaling. INmune Bio has investigated XPro in areas including Alzheimer’s disease and treatment-resistant depression, as well as other conditions associated with neuroinflammation. The company also operates the INKmune platform, which is intended to activate and expand a patient’s own natural killer cells for potential use in cancer immunotherapy. INmune Bio was founded in 2015 and is headquartered in Boca Raton, Florida. The company is led by Raymond J. Tesi, M.D., who serves as chief executive officer and has a background in medicine, immunology and biotechnology. Its development programs are conducted through clinical and research collaborations in the United States and other regions.View INmune Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Exxon's Refining Profits Soared—Did Chevron Get the Same Windfall?LyondellBasell's Dividend Looks Safer, But a New Risk Could Change ThatEli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?Silicon Shock: Intel's 25% Valuation ResetMarketBeat Week in Review – 10/26 - 10/30DoorDash's $17 Billion Bet on Instacart Faces a Long Regulatory Road AheadAmazon's Record Margins Couldn't Stop the Sell-Off—Here's Why Upcoming Earnings Marriott International (11/2/2026)Diamondback Energy (11/2/2026)Williams Companies (11/2/2026)Vertex Pharmaceuticals (11/2/2026)Realty Income (11/2/2026)Apple (11/2/2026)Palantir Technologies (11/2/2026)Entergy (11/2/2026)Booking (11/3/2026)Ferrari (11/3/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
